Literature DB >> 9326655

Interferon beta transduction of peripheral blood lymphocytes from HIV-infected donors increases Th1-type cytokine production and improves the proliferative response to recall antigens.

V Vieillard1, I Cremer, E Lauret, W Rozenbaum, P Debré, B Autran, E De Maeyer.   

Abstract

We are developing a gene therapy method of HIV infection based on the constitutive low production of interferon (IFN) beta. Peripheral blood lymphocytes (PBL) from HIV-infected patients at different clinical stages of infection were efficiently transduced with the HMB-HbHuIFNbeta retroviral vector. The constitutive low production of IFN-beta in cultured PBL from HIV-infected patients resulted in a decreased viral production and an enhanced survival of CD4+ cells, and this protective effect was observed only in the PBL derived from donors having a CD4+ cell count above 200 per mm3. In IFN-beta-transduced PBL from healthy and from HIV-infected donors, the production of the Th1-type cytokines IFN-gamma and interleukin (IL)-12 was enhanced. In IFN-beta-transduced PBL from HIV-infected donors, the production of IL-4, IL-6, IL-10, and tumor necrosis factor alpha was maintained at normal levels, contrary to the increased levels produced by the untransduced PBL. The proliferative response to recall antigens was partially restored in IFN-beta-transduced PBL from donors with an impaired antigen response. Thus, in addition to inhibiting HIV replication, IFN-beta transduction of PBL from HIV-infected donors improves several parameters of immune function.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9326655      PMCID: PMC23550          DOI: 10.1073/pnas.94.21.11595

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Early T-helper cell defects in HIV infection.

Authors:  G M Shearer; M Clerici
Journal:  AIDS       Date:  1991-03       Impact factor: 4.177

2.  An improved retroviral vector for gene transfer into undifferentiated cells.

Authors:  R G Hawley; L A Sabourin; T S Hawley
Journal:  Nucleic Acids Res       Date:  1989-05-25       Impact factor: 16.971

3.  Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging.

Authors:  M Clerici; N I Stocks; R A Zajac; R N Boswell; D R Lucey; C S Via; G M Shearer
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

4.  Polymorphism and gene conversion in mouse alpha-globin haplotypes.

Authors:  M A Erhart; K Piller; S Weaver
Journal:  Genetics       Date:  1987-03       Impact factor: 4.562

5.  HIV replication can be blocked by recombinant human interferon beta.

Authors:  B Michaelis; J A Levy
Journal:  AIDS       Date:  1989-01       Impact factor: 4.177

6.  Downregulation of interferon alpha but not gamma receptor expression in vivo in the acquired immunodeficiency syndrome.

Authors:  A S Lau; S E Read; B R Williams
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

7.  Long-term follow-up of 120 patients with AIDS-related Kaposi's sarcoma treated with interferon alpha-2a.

Authors:  W Rozenbaum; S Gharakhanian; M S Navarette; R De Sahb; B Cardon; C Rouzioux
Journal:  J Invest Dermatol       Date:  1990-12       Impact factor: 8.551

8.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

9.  Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial.

Authors:  H C Lane; V Davey; J A Kovacs; J Feinberg; J A Metcalf; B Herpin; R Walker; L Deyton; R T Davey; J Falloon
Journal:  Ann Intern Med       Date:  1990-06-01       Impact factor: 25.391

10.  T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons.

Authors:  J Estaquier; T Idziorek; W Zou; D Emilie; C M Farber; J M Bourez; J C Ameisen
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

View more
  5 in total

1.  Transfer of human CD4(+) T lymphocytes producing beta interferon in Hu-PBL-SCID mice controls human immunodeficiency virus infection.

Authors:  V Vieillard; S Jouveshomme; N Leflour; E Jean-Pierre; P Debre; E De Maeyer; B Autran
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

2.  Primary immune effects of eukaryotic expression plasmids encoding two hyperactive mutants of human soluble B lymphocyte stimulator.

Authors:  Guangyu Chen; Hongwu Du; Zhengjian Zhang; Shanyun Peng; Donggang Xu; Jiaxi Wang
Journal:  J Clin Immunol       Date:  2005-09       Impact factor: 8.317

3.  ISG15 modification of filamin B negatively regulates the type I interferon-induced JNK signalling pathway.

Authors:  Young Joo Jeon; Joon Seok Choi; Jung Yun Lee; Kyung Ryun Yu; Sangman Michael Kim; Seung Hyeun Ka; Kyu Hee Oh; Keun Il Kim; Dong-Er Zhang; Ok Sun Bang; Chin Ha Chung
Journal:  EMBO Rep       Date:  2009-03-06       Impact factor: 8.807

4.  The relationship between simian immunodeficiency virus RNA levels and the mRNA levels of alpha/beta interferons (IFN-alpha/beta) and IFN-alpha/beta-inducible Mx in lymphoid tissues of rhesus macaques during acute and chronic infection.

Authors:  Kristina Abel; Michelle J Alegria-Hartman; Kristina Rothaeusler; Marta Marthas; Christopher J Miller
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

5.  Low autocrine interferon beta production as a gene therapy approach for AIDS: Infusion of interferon beta-engineered lymphocytes in macaques chronically infected with SIVmac251.

Authors:  Wilfried Gay; Evelyne Lauret; Bertrand Boson; Jérome Larghero; Franck Matheux; Sophie Peyramaure; Véronique Rousseau; Dominique Dormont; Edward De Maeyer; Roger Le Grand
Journal:  Retrovirology       Date:  2004-09-25       Impact factor: 4.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.